This article has Open Peer Review reports available.
The effect of Fucus vesiculosus, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: a case report
© Skibola; licensee BioMed Central Ltd. 2004
Received: 14 January 2004
Accepted: 04 August 2004
Published: 04 August 2004
Rates of estrogen-dependent cancers are among the highest in Western countries and lower in the East. These variations may be attributable to differences in dietary exposures such as higher seaweed consumption among Asian populations. The edible brown kelp, Fucus vesiculosus (bladderwrack), as well as other brown kelp species, lower plasma cholesterol levels. Since cholesterol is a precursor to sex hormone biosynthesis, kelp consumption may alter circulating sex hormone levels and menstrual cycling patterns. In particular, dietary kelp may be beneficial to women with or at high risk for estrogen-dependent diseases. To test this, bladderwrack was administered to three pre-menopausal women with abnormal menstrual cycling patterns and/or menstrual-related disease histories.
Intake of bladderwrack was associated with significant increases in menstrual cycle lengths, ranging from an increase of 5.5 to 14 days. In addition, hormone measurements ascertained for one woman revealed significant anti-estrogenic and progestagenic effects following kelp administration. Mean baseline 17β-estradiol levels were reduced from 626 ± 91 to 164 ± 30 pg/ml (P = 0.04) following 700 mg/d, which decreased further to 92.5.0 ± 3.5pg/ml (P = 0.03) with the1.4 g/d dose. Mean baseline progesterone levels rose from 0.58 ± 0.14 to 8.4 ± 2.6 ng/ml with the 700 mg/d dose (P = 0.1), which increased further to 16.8 ± 0.7 ng/ml with the 1.4 g/d dose (P = 0.002).
These pilot data suggest that dietary bladderwrack may prolong the length of the menstrual cycle and exert anti-estrogenic effects in pre-menopausal women. Further, these studies also suggest that seaweed may be another important dietary component apart from soy that is responsible for the reduced risk of estrogen-related cancers observed in Japanese populations. However, these studies will need to be performed in well-controlled clinical trials to confirm these preliminary findings.
Epidemiological studies show that incidence rates of estrogen-dependent diseases such as cancers of the breast, endometrium and ovary are among the highest in Western, industrialized countries, while rates are much lower in China and Japan [1, 2]. These disparities may be attributable, in part, to differences in dietary and environmental exposures associated with affluent and modern lifestyles that promote estrogenic stimulation and hormone imbalances [3–5]. Although the mechanisms are not fully understood, epidemiological and experimental data suggest that exposure to estrogens, through endogenous production and exogenous exposures resulting in an imbalance in the estrogen/progesterone ratio, may be the most critical determinants in disease risk [6–8]. In estrogen-sensitive tissues, estrogen triggers cell proliferation, and through prolonged stimulation, hyperplasia  and possibly neoplasia can occur. Reproductive factors associated with increased exposure to menstruation resulting in persistent and sustained estrogenic stimulation, such as shorter menstrual cycles, reduced parity, early menarche, and late menopause, are known to increase risk of endometriosis and estrogen-dependent cancers [10, 11], while post-menopausal obesity, hormone replacement therapy and alcohol consumption may be associated with increased breast cancer risk [12–14]. Therefore, limiting exposure to estrogens and reducing the overall number of menstrual cycles in one's lifetime through dietary and lifestyle changes may be the simplest means to reduce disease risk. In particular, the identification of dietary compounds that have estrogen- reducing effects holds great promise in developing chemopreventive strategies to abrogate risk of these diseases.
Studies show that Japanese women have longer menstrual cycle lengths (greater than the 28 day average) and lower circulating estrogen levels compared to Western populations [15–17], which until now has been at least partly attributed to the increased intake of soy protein among Asian populations [18–20]. Another less explored component but main staple of the Japanese diet is seaweed, which accounts for approximately 10–25% of their food intake [21, 22]. Other reported estimated daily intakes are as high as 3–13 g/day . A major source of dietary seaweed among Japanese populations is the edible brown kelp, wakame (Undaria pinnatifida) and kombu (Laminaria japonica). These species and the Atlantic brown kelp, bladderwrack (Fucus vesiculosus), have been shown to exert powerful anti-hypertensive activity related to angiotensin-I-converting enzyme inhibition , to possess antibacterial and antioxidant properties related to their high polyphenolic content , and to prevent dioxin absorption and accelerate dioxin excretion in rats . Other chemopreventive properties such as antiviral activity [27, 28], immunostimulatory effects , anti-proliferative effects on 7,12-dimethylbenz(a)-anthracene-induced rat mammary tumors [30, 31], and anti-tumor and anti-metastatic activities in xenograft mouse models , have been associated with the high level of sulfated polysaccharides, also known as fucoidans, found in brown seaweed.
Intake of bladderwrack, as well as other brown kelp species, also has been shown to alter cholesterol metabolism and to significantly lower plasma cholesterol levels [33, 34]. A possible mechanism of action involves competitive inhibition by fucosterols found in kelp. Since cholesterol is the precursor involved in steroid hormone biosynthesis, a reduction in cholesterol bioavailability could lower circulating plasma 17β-estradiol levels that may lead to alterations in menstrual cycling patterns in pre-menopausal women. Until now, no studies have been performed in humans to determine the effects of brown kelp on menstrual cycling patterns and sex hormone status in pre-menopausal women, particularly in women with or at risk for estrogen-dependent diseases. To explore the hypothesis that kelp consumption could reduce circulating17β-estradiol levels and attenuate menstrual cycle irregularities, bladderwrack was administered to three pre-menopausal women with abnormal menstrual cycling patterns and/or menstrual-related disease histories.
Study Subject Characteristics
Body weight (lb)
Menstrual cycle history
Medical conditions/health status
hypermenorrhea, polymenorrhea, dysmenorrhea, luteal phase deficiency
endometriosis; otherwise healthy
hypermenorrhea, polymenorrhea, dysmenorrhea
general good health
endometriosis; otherwise healthy
The protocol was approved by the Committee for the Protection of Human Subjects of the University of California at Berkeley. The nature of the study was explained, and written informed consent was obtained from all study subjects.
Source and dose of bladderwrack (Fucus vesiculosus)
Dried, powdered bladderwrack was obtained from Maine Coast Sea Vegetables (Franklin, ME) and encapsulated in 350 mg capsules. Two capsules were administered daily for the low dose treatment (700 mg) and four capsules were administered daily for the high dose treatment (1.4 g). Bladderwrack dosage levels were chosen to fall within the range of reported dietary seaweed intakes (10–25%) of the total diet reported for Japanese populations [21, 22]. This was calculated by assuming a total 500 g/d total dietary intake and a range between 50–125 g/d (wet weight) or 0.5–1.25 g/d (dry weight) seaweed intake. This calculation falls below the estimated 3–13 g/d intake reported by Teas et al. .
Treatment protocol and timeline
Pretreatment menstrual cycling history obtained
Pretreatment serum 17β-estradiol and progesterone levels ascertained (Cycle and day)
Treatment serum 17β-estradiol and progesterone levels ascertained (Cycle and day)
Treatment serum 17β-estradiol and progesterone levels ascertained (Cycle and day)
Cycle 2, day 12; Cycle 3, day 12
Cycle 4–5/ 700 mg/d
Cycle 4, day 12; Cycle 4, day 21; Cycle 5, day 21
Cycle 6–7/ 1.4 g/d
Cycle 6, day 21; Cycle 7, day 21
Cycle 4–5/ 700 mg/d
Cycle 4–5/ 700 mg/d
Cycle 6–7/ 1.4 g/d
All hormone assays were performed by Quest Laboratories (San Diego, CA), an outside-certified clinical laboratory. Serum 17β-estradiol and progesterone levels were measured in duplicate by radioimmunoassays. Blank and control sera were run with each assay. The coefficient of variation (a measure of laboratory error) was consistently low (<15%) for 17β-estradiol and progesterone.
Statistical analyses were performed by unpaired t-tests (2-sided) with a commercially available statistical software package (Stata, College Station, Texas). All statistical tests were considered significant for p ≤ 0.05. Results are referred to as borderline significant for 0.05 < p ≤ 0.10.
There were no adverse side effects reported and bladderwrack was well tolerated by all three women.
Effects of treatment on length of menstrual cycle and total days of menstruation
Subject 1 also reported an ovulatory cycle following 2 months on the 700 mg/d kelp intervention, and continued to have ovulatory cycles while on the 1.4 g/d dose.
Effects of treatment on serum estradiol and progesterone levels
Average circulating plasma 17β-estradiol and progesterone levels prior to and during kelp intervention for Subject 1
Pre-treatment baseline levels
700 mg/d dose
1.4 g/d dose
626 ± 91
164 ± 30
92.5 ± 3.5
0.58 ± 0.14
8.4 ± 2.6
16.8 ± 0.7
Discussion of clinical findings
The results of this preliminary pilot study suggest that bladderwrack consumption can effectively increase the length of the menstrual cycle and reduce the total number of days of menstruation in pre-menopausal women. These effects were most marked in the two women that had shorter than average cycles (16 and 23 days) versus the normal range of 26 to 32 days seen in women in Western populations. Menstrual cycles were further lengthened with increasing dose, which may suggest a linear dose-response effect. However, since there was not a sufficient washout period between the 700 and 1400 mg/d doses, an effect of length of time of dosing rather than a dose response effect cannot be ruled out. Nonetheless, these marked increases in menstrual cycle length may have beneficial health effects in lowering risk of estrogen-dependent diseases such as endometriosis and ovarian, endometrial, and breast cancers as reported in a number of studies [16, 35–38]. Menstrual characteristics are surrogate markers that may reflect a woman's overall exposure to and production of endogenous hormones. Shorter menstrual cycle lengths and prolonged menstruation confer longer follicular and luteal phases where estrogen and progesterone levels and endometrial and breast cell proliferation rates are at their highest. A nearly fourfold increase in mitotic activity in the breast lobules occurs during the luteal phase of the menstrual cycle , while the highest proliferation rates (nearly 100-fold) in the endometrium occur during the follicular phase . Therefore, fewer menstrual cycles over a woman's lifetime would decrease the amount of time during which the breast and endometrial epithelia would be exposed to high levels of proliferation, which may decrease overall disease risk.
Bladderwrack consumption also led to a marked reduction in circulating 17β-estradiol levels and an increase in progesterone levels in a subject who exhibited high serum estrogen levels and progesterone deficiency prior to the intervention. While estrogen's proliferative effects on mammary gland development and endometrial and breast tumorigenesis are well documented, progesterone's role in these processes is not as well defined. Studies show that progesterone deficiency is associated with increased endometrial cancer incidence , and that progesterone inhibits estrogen-induced luminal epithelial proliferation in the uterus . However, progesterone has been shown to both stimulate and inhibit the growth of experimental mammary tumors , and the use of synthetic progestins in hormone replacement therapy has been associated with an increased risk of breast cancer . Experimental rat models have elucidated progesterone's vital role in pregnancy-induced morphological changes in the breast, which confer protection against breast cancer . Further, epidemiological studies suggest that it is not pregnancy alone but early first parity and increasing number of pregnancies that are associated with reduced breast cancer risk [45, 46]. These studies suggest that the effects of progesterone in breast cancer risk may be dependent on timing and the type and level of progesterone/progestin exposure. Thus, the anti-estrogenic/progestagenic activity of kelp observed in this study warrants further investigation in its role in breast cancer and other hormone-dependent diseases.
Due to the small number of subjects and the lack of a control group, this study will need to be repeated in a larger, randomized population of women with placebo controls. Other weaknesses of the present study are the lack of data on luteinizing hormone and follicular stimulating hormone levels which would provide pertinent information regarding the effects of dietary bladderwrack on ovulation and the luteal and follicular phases of the menstrual cycle. The potential beneficial impact that dietary bladderwrack may have on abrogating symptoms of endometriosis warrants a closer look at a larger population of women suffering from this disease. However, studies should also be performed in women with normal menstrual cycles who have sex hormone levels within clinically normal ranges to determine the impact of dietary kelp on menstrual cycling patterns and hormone levels in the general population.
The observed responses to bladderwrack consumption in this study suggest that dietary modification may lead to significant changes in the regulation of the menstrual cycle by increasing the length of the cycle, stimulating ovulation, and lowering the estrogen/progesterone ratio in pre-menopausal women. Such changes may be beneficial particularly with regard to women at high risk of estrogen-dependent diseases or who are experiencing fertility problems. Results from these preliminary experiments also suggest that bladderwrack administration may alleviate hypermenorrhea and dysmenorrhea, which may provide some relief in the treatment of endometriosis. Although these reported effects are generally in a beneficial direction, their clinical significance is yet to be determined in a well-controlled study.
The critical role of hormones in breast, endometrial, and ovarian cancers in women and prostate cancer in men has long been recognized. Given the vast rise of these cancers in the U.S. and our limited success with prevention and treatment, there is clearly a need for the identification of novel, non-cytotoxic chemopreventive agents. Future investigations should clarify the role of bladderwrack and other seaweed species on estrogen and progesterone metabolism, to evaluate its potential binding affinity to estrogen and progesterone receptors, and to determine its effects on proliferation in hormone-sensitive tissues. These investigations should also be expanded to include effects of bladderwrack on other sex hormones including the androgens and gonadotropins. In this regard, animal and in vitro studies are currently underway in our laboratory to elucidate the potential mechanisms and clinical relevance of bladderwrack bioactivity, and to identify and isolate the active components involved.
Written consent was obtained from the patients for publication of study. This work was supported by the National Foundation for Cancer Research and NIH grant P30 ES01896. Thanks to Dr. Martyn T. Smith for his guidance and support.
- Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999, 80: 827-841. 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin. 1999, 49: 33-64, 1.View ArticlePubMedGoogle Scholar
- Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN: Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control. 1998, 9: 199-207. 10.1023/A:1008838412423.View ArticlePubMedGoogle Scholar
- McTiernan A: Behavioral risk factors in breast cancer: can risk be modified?. Oncologist. 2003, 8: 326-334.View ArticlePubMedGoogle Scholar
- Tavani A, Bosetti C, Dal Maso L, Giordano L, Franceschi S, La Vecchia C: Influence of selected hormonal and lifestyle factors on familial propensity to ovarian cancer. Gynecol Oncol. 2004, 92: 922-926. 10.1016/j.ygyno.2003.11.038.View ArticlePubMedGoogle Scholar
- Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999, 130: 270-277.View ArticlePubMedGoogle Scholar
- Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998, 90: 1292-1299. 10.1093/jnci/90.17.1292.View ArticlePubMedGoogle Scholar
- Baskin GB, Smith SM, Marx PA: Endometrial hyperplasia, polyps, and adenomyosis associated with unopposed estrogen in rhesus monkeys (Macaca mulatta). Vet Pathol. 2002, 39: 572-575. 10.1354/vp.39-5-572.View ArticlePubMedGoogle Scholar
- Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL: Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 2003, 86: 477-486. 10.1016/S0960-0760(03)00377-7.View ArticlePubMedGoogle Scholar
- Hinkula M, Pukkala E, Kyyronen P, Kauppila A: Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer. 2002, 98: 912-915. 10.1002/ijc.10267.View ArticlePubMedGoogle Scholar
- Daniels M, Merrill RM, Lyon JL, Stanford JB, White GL: Associations between breast cancer risk factors and religious practices in Utah. Prev Med. 2004, 38: 28-38. 10.1016/j.ypmed.2003.09.025.View ArticlePubMedGoogle Scholar
- Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson H. E., Jr., Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003, 95: 1218-1226.View ArticlePubMedGoogle Scholar
- Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14065-2.View ArticlePubMedGoogle Scholar
- Tjonneland A, Thomsen BL, Stripp C, Christensen J, Overvad K, Mellemkaer L, Gronbaek M, Olsen JH: Alcohol intake, drinking patterns and risk of postmenopausal breast cancer in Denmark: a prospective cohort study. Cancer Causes Control. 2003, 14: 277-284. 10.1023/A:1023640720385.View ArticlePubMedGoogle Scholar
- Shimizu H, Ross RK, Bernstein L, Pike MC, Henderson BE: Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan. Br J Cancer. 1990, 62: 451-453.View ArticlePubMedPubMed CentralGoogle Scholar
- Olsson H, Landin-Olsson M, Gullberg B: Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease. J Natl Cancer Inst. 1983, 70: 17-20.PubMedGoogle Scholar
- Key TJ, Chen J, Wang DY, Pike MC, Boreham J: Sex hormones in women in rural China and in Britain. Br J Cancer. 1990, 62: 631-636.View ArticlePubMedPubMed CentralGoogle Scholar
- Lu LJ, Anderson KE, Grady JJ, Kohen F, Nagamani M: Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res. 2000, 60: 4112-4121.PubMedGoogle Scholar
- Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M: Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr. 1984, 40: 569-578.PubMedGoogle Scholar
- Cassidy A, Bingham S, Setchell KD: Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr. 1994, 60: 333-340.PubMedGoogle Scholar
- Kagawa Y: Impact of Westernization on the nutrition of Japanese: changes in physique, cancer, longevity and centenarians. Prev Med. 1978, 7: 205-217. 10.1016/0091-7435(78)90246-3.View ArticlePubMedGoogle Scholar
- Wood CG: Seaweed extracts: a unique ocean resource. J Chem Educ. 1974, 51: 449-452.View ArticlePubMedGoogle Scholar
- Teas J, Hebert JR, Fitton JH, Zimba PV: Algae - a poor man's HAART?. Med Hypotheses. 2004, 62: 507-510. 10.1016/j.mehy.2003.10.005.View ArticlePubMedGoogle Scholar
- Sato M, Oba T, Yamaguchi T, Nakano T, Kahara T, Funayama K, Kobayashi A: Antihypertensive effects of hydrolysates of wakame (Undaria pinnatifida) and their angiotensin-I-converting enzyme inhibitory activity. Ann Nutr Metab. 2002, 46: 259-267. 10.1159/000066495.View ArticlePubMedGoogle Scholar
- Abdussalam S: Drugs from seaweeds. Med Hypotheses. 1990, 32: 33-35. 10.1016/0306-9877(90)90064-L.View ArticlePubMedGoogle Scholar
- Morita K, Nakano T: Seaweed accelerates the excretion of dioxin stored in rats. J Agric Food Chem. 2002, 50: 910-917. 10.1021/jf0111920.View ArticlePubMedGoogle Scholar
- Luscher-Mattli M: Polyanions--a lost chance in the fight against HIV and other virus diseases?. Antivir Chem Chemother. 2000, 11: 249-259.View ArticlePubMedGoogle Scholar
- Schaeffer DJ, Krylov VS: Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol Environ Saf. 2000, 45: 208-227. 10.1006/eesa.1999.1862.View ArticlePubMedGoogle Scholar
- Cooper R, Dragar C, Elliot K, Fitton J, Godwin J, Thompson K: GFS, a preparation of Tasmanian Undaria pinnatifida is associated with healing and inhibition of reactivation of Herpes. BMC Complement Altern Med. 2002, 2: 11-10.1186/1472-6882-2-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Funahashi H, Imai T, Tanaka Y, Tsukamura K, Hayakawa Y, Kikumori T, Mase T, Itoh T, Nishikawa M, Hayashi H, Shibata A, Hibi Y, Takahashi M, Narita T: Wakame seaweed suppresses the proliferation of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors in rats. Jpn J Cancer Res. 1999, 90: 922-927.View ArticlePubMedGoogle Scholar
- Teas J, Harbison ML, Gelman RS: Dietary seaweed (Laminaria) and mammary carcinogenesis in rats. Cancer Res. 1984, 44: 2758-2761.PubMedGoogle Scholar
- Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H: Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol. 2003, 65: 173-179. 10.1016/S0006-2952(02)01478-8.View ArticlePubMedGoogle Scholar
- Ara J, Sultana V, Qasim R, Ahmad VU: Hypolipidaemic activity of seaweed from Karachi coast. Phytother Res. 2002, 16: 479-483. 10.1002/ptr.909.View ArticlePubMedGoogle Scholar
- Kaneda T, Tokuda S, Arai K: Studies on the effects of marine products on cholesterol metabolism, 1. The effects of edible seaweed. Bulletin Jap Soc Sci Fish. 1963, 29: 1020-1035.View ArticleGoogle Scholar
- Xu WH, Xiang YB, Ruan ZX, Zheng W, Cheng JR, Dai Q, Gao YT, Shu XO: Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. Int J Cancer. 2004, 108: 613-619. 10.1002/ijc.11598.View ArticlePubMedGoogle Scholar
- Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC: Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003, 104: 228-232. 10.1002/ijc.10927.View ArticlePubMedGoogle Scholar
- Frackiewicz EJ: Endometriosis: an overview of the disease and its treatment. J Am Pharm Assoc (Wash). 2000, 40: 645-57; quiz 699-702.View ArticleGoogle Scholar
- Beiler JS, Zhu K, Hunter S, Payne-Wilks K, Roland CL, Chinchilli VM: A case-control study of menstrual factors in relation to breast cancer risk in African-American women. J Natl Med Assoc. 2003, 95: 930-938.PubMedPubMed CentralGoogle Scholar
- Ramakrishnan R, Khan SA, Badve S: Morphological changes in breast tissue with menstrual cycle. Mod Pathol. 2002, 15: 1348-1356. 10.1097/01.MP.0000039566.20817.46.View ArticlePubMedGoogle Scholar
- Felix JC, Farahmand S: Endometrial glandular proliferation and estrogen receptor content during the normal menstrual cycle. Contraception. 1997, 55: 19-22. 10.1016/S0010-7824(96)00242-9.View ArticlePubMedGoogle Scholar
- Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B: Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998, 147: 1038-1042.View ArticlePubMedGoogle Scholar
- Lai MD, Jiang MJ, Wing LY: Estrogen stimulates expression of p21Waf1/Cip1 in mouse uterine luminal epithelium. Endocrine. 2002, 17: 233-239. 10.1385/ENDO:17:3:233.View ArticlePubMedGoogle Scholar
- Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. Jama. 2003, 289: 3254-3263. 10.1001/jama.289.24.3254.View ArticlePubMedGoogle Scholar
- Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S: Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci U S A. 1999, 96: 2520-2525. 10.1073/pnas.96.5.2520.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee SH, Akuete K, Fulton J, Chelmow D, Chung MA, Cady B: An increased risk of breast cancer after delayed first parity. Am J Surg. 2003, 186: 409-412. 10.1016/S0002-9610(03)00272-1.View ArticlePubMedGoogle Scholar
- Oran B, Celik I, Erman M, Baltali E, Zengin N, Demirkazik F, Tezcan S: Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study. Med Oncol. 2004, 21: 31-40. 10.1385/MO:21:1:31.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/4/10/prepub
This article is published under license to BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.